A couple of women on Twitter drew attention the past week to this September 1 article in Telegraph by Laura Donnelly.
According to the article, The National Institute of Health and Care Excellence said there was a lack of evidence to prove that the drug called fulvestrant extended lives.
Studies that said fulvestrant "stalls the cancer’s growth by around three months" were seen as weak on research.
Also NHS feel it is too expensive compared to other available drugs. So over a thousand women will apparently not get the drug until it is studied further.
The article says Fulvestrant is "licensed for women with oestrogen-receptor positive cancer, who have not already had other forms of hormonal treatment." (my bolding)
Right there I began to find different takes on the drug as used in the states.
Medline Plus for instance seems to find different rules on who is eligible here for the drug:
"Fulvestrant is used to treat hormone receptor positive breast cancer (breast cancer that depends on hormones such as estrogen to grow) in women who have experienced menopause (change of life; end of monthly menstrual periods) " and whose breast cancer has worsened after they were treated with antiestrogen medications such as tamoxifen (Nolvadex). (Bolding mine.)